Charlottenlund, Denmark

Ross Stephens


Average Co-Inventor Count = 6.0

ph-index = 1

Forward Citations = 9(Granted Patents)


Company Filing History:


Years Active: 2006

Loading Chart...
1 patent (USPTO):Explore Patents

Title: Ross Stephens: Innovator in Cancer Research from Charlottenlund, Denmark

Introduction

Ross Stephens is a distinguished inventor based in Charlottenlund, Denmark, known for his contributions to cancer research through innovative approaches in biochemistry. With a focus on peptide antagonists and their therapeutic potentials, his work aims to enhance the treatment options available for cancer patients.

Latest Patents

Ross holds a patent titled "Peptide antagonists of the human urokinase receptor and method for selecting them." This groundbreaking invention introduces a novel set of inhibitors that disrupt the binding interaction between human urokinase plasminogen activator (uPA) and its cell surface receptor (uPAR). The inhibitors consist of peptide fragments, which can be in monomeric form or multiple copies attached to a common scaffold. The amino acid sequence of these peptides may include uncommon substituted amino acids, which can partially consist of peptoid sequences. The invention also encompasses the therapeutic use of such peptides, particularly for cancer treatment, highlighting the development of a modified non-human mammalian receptor that these novel inhibitors target.

Career Highlights

Currently, Ross Stephens is associated with the Cancer Research Foundation of 1989 (Fonden Til Fremme Af Experimentel Cancerforskning). Through his role, he has played a pivotal part in advancing cancer research, with his patent being a testament to his innovative spirit and dedication to improving patient outcomes.

Collaborations

In his journey, Ross has collaborated with esteemed colleagues, including Michael Ploug and Søren Østergaard. These partnerships have fostered an environment for groundbreaking research and innovation, leading to significant developments in cancer therapies.

Conclusion

Ross Stephens is a notable figure in the field of cancer research, with significant contributions exemplified by his patent on peptide antagonists. His ongoing work, in collaboration with colleagues, continues to push the boundaries of cancer therapy, promising improved treatments for patients worldwide.

This text is generated by artificial intelligence and may not be accurate.
Please report any incorrect information to support@idiyas.com
Loading…